TOSEDOSTAT PLUS LOW DOSE CYTARABINE COMBO INDUCES A HIGH RATE OF RESPONSES THAT CAN BE PREDICTED BY GENETIC PROFILING IN AML: FINAL RESULTS OF A PHASE II MULTICENTER STUDY

被引：0
|
作者：
Visani, G. [1 ]
Loscocco, F. [1 ]
Fuligni, F. [2 ]
Zuffa, E. [3 ]
Sensi, A. [4 ]
Zaccaria, A. [3 ]
Musuraca, G. [5 ]
Giannini, B. [4 ]
Lucchesi, A. [5 ]
Fabbri, F. [5 ]
Mianulli, A. M. [6 ]
Tosi, P. [6 ]
Tonelli, M. [4 ]
Candoni, A. [7 ]
Fanin, R. [7 ]
Sparaventi, G. [1 ]
Gobbi, M. [8 ]
Clavio, M. [8 ]
Rocchi, M. [9 ]
Piccaluga, P. [2 ]
Isidori, A. [1 ]
机构：
[1] Hematol & Stem Cell Transplant Ctr, AORMN, Pesaro, Italy
[2] Univ Bologna, S Orsola M Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Hematopatol Sect, Bologna, Italy
[3] Ravenna Hosp, Hematol, Ravenna, Italy
[4] Ctr Serv Lab Unico AVR, Genet Med, Pievesestina Di Cesana, Italy
[5] IRST Meldola, Oncohematol, Meldola, Italy
[6] Rimini Hosp, Hematol, Rimini, Italy
[7] Azienda Osped Univ S Maria Misericordia, Ctr Trapianti & Terapie Cellulari Carlo Melzi DIS, Clin Ematol, Udine, Italy
[8] Univ Genoa, Hematol, Genoa, Italy
[9] Univ Urbino, Inst Biomath, I-61029 Urbino, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P564
引用
收藏
页码：215 / 215
页数：1
相关论文
共 44 条
  • [21] Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS)
    Macdonald, D. A.
    Assouline, S. E.
    Brandwein, J.
    Kamel-Reid, S.
    Eisenhauer, E. A.
    Couban, S.
    Foo, A.
    Leber, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Randomized phase II study of clofarabine versus clofarabine plus low-dose cytarabine (ara-C) for patients (pts) ≥ 60 years (yrs) with newly diagnosed acute myeloid leukemia (AML).
    Faderl, S
    Ravandi-Kashani, F
    Ferrajoli, A
    Estrov, Z
    Wierda, W
    Verstovsek, S
    Garcia-Manero, G
    Estey, EE
    Kwari, M
    Kantarjian, HM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 591S - 591S
  • [23] Prospective Multicenter Phase II Study of Myeloablative Conditioning of Iv Busulfan, Fludarabine plus /- Low Dose TBI Intensified by G-CSF-Priming and Cytarabine for Myeloid Malignancies in Older Patients (≥55 Years): Final Analysis of the JS']JSCT FB13 Study
    Uchida, Naoyuki
    Eto, Tetsuya
    Sakura, Toru
    Aisa, Yoshinobu
    Fujishima, Naohito
    Gomyo, Hiroshi
    Nishikawa, Akinori
    Maeda, Yoshinobu
    Miyamoto, Toshihiro
    Nagafuji, Koji
    Kishimoto, Junji
    Teshima, Takanori
    Taniguchi, Shuichi
    Harada, Mine
    Akashi, Koichi
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S351 - S351
  • [24] Treatment of relapse of AML and MDS after allogeneic stem cell transplantation using low-dose chemotherapy, donor PBSC and GMCSF: Final results from a prospective, multicenter phase II trial by the German cooperative transplant group
    Schmid, Christoph
    Tischer, Johanna
    Steljes, Matthias
    Schleuning, Michael
    Schwerdtfeger, Rainer
    Hegenbart, Ute
    Schubert, Joerg
    Vogel, Wichard
    Gruhn, Berd
    Lallinger, Christiane
    Ledderose, Georg
    Bornhaeuser, Martin
    Kienast, Joachim
    Kolb, Hans-Jochem
    BLOOD, 2007, 110 (11) : 492A - 492A
  • [25] Continued low-dose decitabine (DAC) is an active first-line treatment.: In all cytogenetic subgroups of older AML patients:: Results of the FR00331 multicenter phase II study
    Luebbert, Michael
    Rueter, Bjorn
    Claus, Rainer
    Schmid, Mathias
    Germing, Ulrich
    Eimeracher, Hartmut
    Ganser, Arnold
    Platzbecker, Uwe
    Galm, Oliver
    Brugger, Wolfram
    Heil, Gerhard
    Wijermans, Pierre W.
    Pfeifer, Dietmar
    Schmoor, Claudia
    Doehner, Hartmut
    BLOOD, 2007, 110 (11) : 95A - 95A
  • [26] Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML
    Bug, Gesine
    Mueller-Tidow, Carsten
    Schlenk, Richard F.
    Kraemer, Alwin
    Luebbert, Michael
    Krug, Utz
    Voss, Florian
    Taube, Tillmann
    Fritsch, Holger
    Garin-Chesa, Pilar
    Ottmann, Oliver G.
    Doehner, Hartmut
    BLOOD, 2011, 118 (21) : 673 - 673
  • [27] 5-fluorouracil plus high dose levofolinic acid and oral hydroxyurea for the treatment of primary hepatocellular carcinomas: Results of a phase II multicenter study of the southern Italy Oncology Group (GOIM)
    Gebbia, V
    Maiello, E
    Serravezza, G
    Giotta, F
    Testa, A
    Borsellino, N
    Pezzella, G
    Colucci, G
    ANTICANCER RESEARCH, 1999, 19 (2B) : 1407 - 1410
  • [28] Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine
    Bug, Gesine
    Schlenk, Richard F.
    Mueller-Tidow, Carsten
    Luebbert, Michael
    Kraemer, Alwin
    Fleischer, Frank
    Taube, Tillmann
    Ottmann, Oliver G.
    Doehner, Hartraut
    BLOOD, 2010, 116 (21) : 1359 - 1359
  • [29] Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses
    Loges, Sonja
    Sutamtewagul, Grerk
    Heuser, Michael
    Chromik, Joerg
    Kapp-Schwoerer, Silke
    Crugnola, Monica
    Di Renzo, Nicola
    Lemoli, Roberto M.
    Mattei, Daniele Giovanni
    Ben Batalla, Isabel
    Hellesoy, Monica
    Waizenegger, Jonas
    Janning, Melanie
    Imbusch, Charles D.
    Beumer, Niklas
    Rayford, Austin
    Nautiyal, Jaya
    Berkman-Gottlieb, Tzivia
    Micklem, David
    Gabra, Hani
    Gorcea-Carson, Claudia
    Lorens, James B.
    Fiedler, Walter
    Alvarado, Yesid
    Gjertsen, Bjorn T.
    Rieckmann, Lisa-Marie
    BLOOD, 2021, 138
  • [30] A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60years of age
    Buckley, Sarah A.
    Mawad, Raya
    Gooley, Ted A.
    Becker, Pamela S.
    Sandhu, Vicky
    Hendrie, Paul
    Scott, Bart L.
    Wood, Brent L.
    Walter, Roland B.
    Smith, Kelly
    Dean, Carol
    Estey, Elihu H.
    Pagel, John M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (03) : 349 - 355
12345